Toronto, Ontario, Canada, September 23, 2026
Cardiol Therapeutics has announced that its pivotal Phase III MAVERIC clinical trial evaluating CardiolRx™ for recurrent pericarditis has achieved its original enrollment target ahead of schedule. As of September 23, the study had enrolled 110 patients, meeting the company’s initial recruitment target earlier than its previous end-of-September guidance. Following a blinded review of clinical events, the MAVERIC Steering Committee recommended expanding enrollment to up to 150 patients to capture sufficient recurrence events for a robust assessment of CardiolRx’s potential efficacy. The company said the review showed fewer-than-expected pericarditis recurrences, although treatment assignments remain blinded and the observation does not establish whether CardiolRx or placebo is responsible for the observed event rate. With the expanded enrollment, topline Phase III results are now anticipated in mid-2027, compared with the company’s previous expectation of the first quarter of 2027.
MAVERIC Reaches Original Phase III Enrollment Target
The MAVERIC trial is a randomized, double-blind, placebo-controlled, multicenter Phase III study designed to evaluate whether CardiolRx can reduce the risk of recurrent pericarditis episodes. Patients are randomized 1:1 to CardiolRx or placebo, allowing investigators to compare recurrence outcomes while maintaining blinding throughout the study. The trial’s primary efficacy analysis will assess time to the first new episode of pericarditis recurrence, measuring whether treatment can delay or prevent another episode over time. The proportion of patients remaining free from a new recurrence at the end of the study will be evaluated as a secondary endpoint. The study builds on Cardiol Therapeutics’ earlier Phase II MAvERIC-Pilot program, which investigated CardiolRx in patients with recurrent pericarditis and provided clinical evidence supporting continued development of the candidate. The company has also reported that the Phase III study was designed with input from the U.S. Food and Drug Administration (FDA).
Trial Expansion Designed to Strengthen Efficacy Analysis
The decision to increase enrollment from 110 to as many as 150 patients follows a blinded review showing a lower level of recurrence than anticipated when the study was designed. Because MAVERIC’s statistical analysis depends on accumulating a sufficient number of recurrence events, the Steering Committee recommended additional enrollment to help preserve the trial’s planned statistical power and strengthen the eventual efficacy assessment. Importantly, the company has not reported unblinded efficacy results from the Phase III trial, so the current recurrence observation cannot be attributed to CardiolRx. The expanded recruitment is therefore intended to ensure that the final analysis has enough events to provide a meaningful assessment of the investigational therapy’s ability to reduce recurrent pericarditis risk. Cardiol Therapeutics expects the additional enrollment and subsequent follow-up to move the anticipated topline readout to mid-2027. The company has stated that its existing capital is expected to fund completion of MAVERIC, with its projected cash runway extending into the first quarter of 2028.
Advertisement
CardiolRx Targets Inflammatory Heart Disease
CardiolRx is a pharmaceutically manufactured oral solution containing cannabidiol and is being investigated as an anti-inflammatory and anti-fibrotic therapy for cardiovascular disease. Cardiol Therapeutics says its mechanism involves modulation of the inflammasome pathway, an intracellular component of the innate immune system that has been implicated in inflammatory and fibrotic processes associated with pericarditis, myocarditis and heart failure. Recurrent pericarditis is an inflammatory condition affecting the membrane surrounding the heart and can cause chest pain, shortness of breath, fatigue, physical limitations and hospital visits. CardiolRx has received FDA Orphan Drug Designation for pericarditis, including recurrent pericarditis, supporting its development in this disease area. The company is also advancing CRD-38, a subcutaneously administered investigational formulation intended for inflammatory heart disease, including heart failure.
The MAVERIC program represents a major clinical milestone for Cardiol Therapeutics as the company advances CardiolRx toward a potential regulatory submission in recurrent pericarditis. However, the candidate remains investigational, and the current enrollment update should not be interpreted as evidence that the therapy has demonstrated Phase III efficacy. The eventual topline results will provide the key clinical assessment of whether CardiolRx can reduce recurrence risk compared with placebo. Until those data are available, the expanded trial is intended to generate a sufficiently robust dataset for evaluating the candidate’s efficacy and safety. With enrollment now potentially reaching 150 patients, Cardiol Therapeutics is continuing the pivotal study while preparing for the anticipated mid-2027 clinical readout.
Source: Cardiol Therapeutics press release
